Category: Corona Virus Vaccine

The Covid-19 vaccine registration program has already started in our country. Honble Prime Minister Sheikh Hasina inaugurated the Covid-19 vaccine registration program. Those who want to get Covid-19 vaccine have to apply through pre-registration. So those who want to get the Covid-19 vaccine have to register online or through apps. No person will be vaccinated without a pre registration.

Anyone can register for vaccination at home. There are currently two methods for registering to receive the Covid-19 vaccine. One is to register the Covid-19 vaccine using the Surokkha app and the other is to register by visiting the website https://surokkha.gov.bd/. Bangladeshs ICT department has launched the Covid-19 vaccine management system shurokkha app. The Covid-19 vaccine registration program will be completed in 2 steps. Two Language are available in registration for vaccination. One is Bengali and the other is English.

Are you a National University student? Submit your information for getting Covid Vaccine.

To get the Covid-19 vaccination registration form, first visit https://surokkha.gov.bd/After entering the website, you have to click on the registration button. Then one by one registration form will be available by following the given steps. The forms are provided below.

The first step in the Covid-19 vaccine registration process is:

And the citizen class must be selected. This means that the person who wants to be vaccinated has to decide what class or profession he belongs to. The categories that fall within the citizen category are given below.

The Covid-19 vaccine registration process details how to register for the vaccine. Therefore, there is nothing new to say about this. The registration process for vaccination is very simple. So those who are interested in registering for vaccination must follow the prescribed procedure.

After registration for Covid-19 vaccine, the vaccination card has to be collected. To collect the card, you have to download the vaccine card by clicking on the vaccine card download button. An OTP SMS in the form of notification will be sent to the mobile number while downloading the vaccine card.

There will be a number to give SMS, you have to provide that number and download the vaccine. The main reason for this is that no unwanted person other than a certain person can download the vaccine card. The date and place of vaccination will be informed later via SMS or in the form of notification to those who use the app.

Vaccine Covid-19 vaccine has been distributed in almost all healthcare complexes in Bangladesh since February 8. Almost a million people have already been vaccinated with the Covid-19 vaccine. So far no side effects have been reported from this Covid-19 vaccine.

Various types of propaganda have been carried out through various social media. As a result, negative perceptions have been created among the public about the Covid-19 vaccine. Due to which many people have expressed reluctance to take the vaccine. But now many are coming out of this idea. At present, there is such a reaction among the people who are interested in getting the vaccine. However, in some cases, the side effects of the Covid-19 vaccine may occur. They are described below.

Like all other medicines or vaccines, this vaccine has the potential for some side effects. However, in most cases, they are very mild, such as pain, swelling, redness at the injection site, muscle and joint pain, weakness, nausea, fever, fatigue, etc. No serious side effects have been reported so far, according to clinical trials. However, if you have any problem, you must go to the nearest hospital immediately and seek the advice of a doctor.

But there is nothing to worry about. The above symptoms are not uncommon.

The latest news regarding the registration and delivery of Covid-19 vaccine is mentioned below.

What to do if OTP is not received at the last step of the registration process?

You can resend OTP. If you unfortunately close the OTP providing screen, can re-register.

If I want to register for Covid-19 coronavirus vaccine, how do I register online?

You can register by logging on to http://www.surokkha.gov.bd web portal or by downloading the Surokkha app from Google Play Store. See Manual on the web portal for details.

I have registered for the vaccine online, what should I do next?

Download Vaccine Card from http://www.surokkha.gov.bd web portal. Later, the date and center of the vaccine will be informed via SMS on the mobile phone.

How to check the Registration status for Covid-19 vaccine online?

You can know the status of registration by verifying the national identity card and mobile number from the Registration Status menu on the web portal http://www.surokkha.gov.bd.

How can I get a vaccine card for receiving the Covid-19 vaccine?

You can Download Vaccine Card by verifying National Identity Card and Mobile Number from the Vaccine Card Download menu at http://www.surokkha.gov.bd

How do I know the center and date for receiving the vaccine?

After the successful registration for the vaccine, the date and center of the vaccine will be informed via SMS on the mobile phone at a later time.

How many doses of Covid-19 vaccine should be taken?

Two doses of Covid-19 vaccine should be taken.

How can I get a vaccine certificate after completion of Covid-19 vaccine?

After completion of two doses of Covid-19 vaccine, you can collect the vaccine certificate by verifying the national identity card and mobile number from the Vaccine Certificate Download menu at the web portal http://www.suraksha.gov.bd

Who can receive Covid-19 vaccine?

According to the National Covid-19 immunization and action plan, everyone will be vaccinated according to the priority list.

Someone asked, my grandfather is 70 years old but cant get out of bed as paralyzed, how can my grandfather get vaccinated?

Covid-19 immunization activities are service based, so the intended person has to come to the immunization center and get vaccinated.

Who cannot be vaccinated in this campaign?

Covid vaccine cannot be given to any person other than the target population of the registered / included in the line listing. Pregnant mothers and lactating mothers, under 18 years of age, sick and hospitalized, need to request a vaccination from the designated immunization center as advised by the doctor. Vaccination cannot be done against the will of the person.

One asked, will a pregnant woman get this vaccine?

Pregnant women will not be given Covid-19 vaccine for the time being.

NID card is lost, how do I register?

This Covid-19 vaccine will be brought under online registration through National Identity Card. The Covid-19 vaccine will be given to everyone in phases. So come next with an NID or National Identity Card.

No vaccination card has been brought, no information can be seen on the mobile; What to do now?

The vaccinator will ask him to reprint the card and bring it back

Earlier affected by Covid-19 and recovered after treatment, can I get Covid-19 vaccine?

Covid-19 vaccine will be given if listed on priority basis.

28 years old, 5 months pregnant. She works at Covid Hospital; Will Covid-19 get vaccinated?

As the effect of Covid-19 vaccine on pregnant women is not confirmed, pregnant women will not be given Covid-19 vaccine for the time being.

A frontline worker goes home every day after work. So will everyone at home get this vaccine?

Vaccination will be given only on the basis of priority list.

If a person from another center / area comes to get vaccinated during vaccination, can he be vaccinated?

If he/she is included in the list, then he/she can be vaccinated. The vaccinator must update online.

I have to take pressure medicine every day; Can I be vaccinated?

Covid-19 vaccine will be given if listed on priority basis.

I had a heart operation 15 days ago; Can I be vaccinated?

Covid-19 vaccine will be given if healthy and enrolled on priority basis.

Does this vaccine have any side effects?

Like all other medicines or vaccines, this vaccine has the potential for some side effects. However, in most cases, they are very mild, such as pain, swelling, redness at the injection site, muscle and joint pain, weakness, nausea, fever, fatigue etc. No serious side effects have been reported so far, according to clinical trials. However, if you have any problem, you must go to the nearest hospital immediately and seek the advice of a doctor.

[junkie-button url=https://surokkha.gov.bd/static/media/Surokkha_Web_Portal_User_Manual.f376f9b8.pdf style=green size=large type=round target=_blank] Download [/junkie-button]

Contents

Continued here:

Covid-19 Vaccine Registration In Bangladesh - NewResultBD.Com

The EU Digital COVID Certificate Regulation entered into application on 1 July 2021. EU citizens and residents will now be able to have their Digital COVID Certificates issued and verified across the EU.

Learn how to get the certificate from your national health authority by selecting your country on the interactive map below.

As of 1 February 2022, there are new rules in place that establish a binding acceptance period of 9 months for vaccination certificates, used for travel within the EU .

Member States must accept vaccination certificates for a period of 9 months following the administration of the last dose of the primary vaccination. For the Johnson&Johnson vaccine this means 270 days from the first and only shot. For a two-dose vaccine it means 270 days from the second shot, or, in line with the vaccination strategy of the Member State of vaccination, the first and only shot after having recovered from the virus.

Member States should not provide for a different acceptance period for the purposes of travel within the European Union. The standard acceptance period does not apply to certificates for booster doses.

These rules apply only to the vaccination certificates used for the purpose of travel in the EU. Member States may apply different rules when using the EU Digital COVID Certificate in a domestic context, but are invited to align with the acceptance period set at EU level.

A person who has a valid EU Digital COVID Certificate should in principle not be subject to additional restrictions, such as tests or quarantine, regardless of their place of departure in the EU.

Persons without an EU Digital COVID Certificate should be allowed to travel based on a test carried out prior to or after arrival. In addition, they might be required to undergo quarantine/self-isolation when they arrive from particularly affected (dark red) areas.

Any measures restricting free movement must be non-discriminatory and proportionate. Member States should, in principle, not refuse entry to persons travelling from other Member States.

An EU Digital COVID Certificate is a digital proof that a person has either

Yes, children can get an EU Digital COVID Certificate.

The European Medicines Agency (EMA) has given its green light to the use of the BioNTech Pfizer vaccine Comirnaty and the Moderna vaccine Spikevax for children of 12-17 years. Children can also receive a test or recovery certificate. These certificates can also be received by their parents and stored on the parents' smartphone app.

EU Member States also agreed that minors travelling with parents should be exempt from quarantine when the parents do not need to undergo quarantine, for example due to vaccination. Children under 12 should also be exempt from travel-related testing.

National authorities are in charge of issuing the certificate. It could, for example, be issued by test centres or health authorities, or directly via an eHealth portal.

Information on how to get the certificate should be provided by the national health authorities.

The digital version can be stored on a mobile device. Citizens can also request a paper version. Both will have a QR code that contains essential information, as well as a digital signature to make sure the certificate is authentic.

Member States have agreed on a common design that can be used for the electronic and paper versions to facilitate the recognition.

Select your country on the interactive map below to learn how to get the certificate from your national health authority.

So far, 49 non-EU countries (and territories) have joined the EU Digital COVID Certificate system, based on EU equivalence decisions.

The COVID certificates issued in those 49 countries (and territories) are accepted in the EU under the same conditions as the EU Digital COVID Certificate. Likewise, the EU Digital COVID Certificate is accepted by those 49 countries.

The EU Digital COVID Certificate is accepted in all EU Member States. It helps ensure that restrictions currently in place can be lifted in a coordinated manner.

When travelling, the EU Digital COVID Certificate holder should in principle be exempt from free movement restrictions: Member States should refrain from imposing additional travel restrictions on the holders of an EU Digital COVID Certificate, unless they are necessary and proportionate to safeguard public health.

In such a case for instance as a reaction to new variants of concern that Member State would have to notify the Commission and all other Member States and justify this decision.

Yes. The EU Digital COVID Certificate should facilitate free movement inside the EU. It is not a pre-condition to free movement, which is a fundamental right in the EU.

Without a certificate, you might however be subject to restrictions like testing or quarantine. Member States can introduce travel restrictions. Please check Re-openEU for the latest updates.

To ensure that there is no discrimination against individuals who are not vaccinated, the EU Digital COVID Certificate also covers test certificates and certificates for persons who have recovered from COVID-19. This way everyone can benefit from the EU Digital COVID Certificate.

In January 2022, rules on coordination of safe and free movement in the EU were updated to take into account the status of the person instead of the epidemiological situation at regional level, with the exception of areas where the virus is circulating at very high levels.

Frequently asked questions on the EU Digital COVID Certificate, vaccinations and travel restrictions

The Council agreed on an updated framework on 22 February 2022, further facilitating travel to the EU. Member States agreed to apply these updates as of 1 March 2022.

Under this approach, non-EU travellers who are vaccinated with an EU or WHO-approved vaccine should be able to travel to the EU, provided they have received the last dose of the primary vaccination series at least 14 days and no more than 270 days before arrival, or provided they have received a booster dose.

In addition, those who recovered from COVID-19 within 180 days prior to travelling to the EU should be able to travel to the EU if they can prove their recovery with an EU Digital COVID Certificate or a non-EU certificate deemed equivalent to the EU Digital COVID Certificate.

Persons travelling from a country or territory included on the list of countries from where all travel should be possible and who hold proof of a negative PCR test should also be able to travel to the EU. The Council regularly reviews and, where relevant, updates a list of such countries, based on an evaluation of the health situation. All travel to the EU from countries included on this list should be possible, regardless of vaccination status.

In addition, EU citizens and residents, and their family members, as well as those who have an essential reason to come to Europe should continue to be able to do so.

The purpose of the EU Digital COVID Certificate is to help facilitate free movement and travel within the EU for both EU citizens and non-EU nationals already in the EU.

When it comes to proving vaccination status for those travelling from outside the EU, EU Member States could accept vaccination certificates from non-EU countries containing the necessary data (identification of the person, type of vaccine and date of vaccination), taking into account the ability to verify the authenticity, validity and integrity of the certificate.

The EU can also decide to automatically recognise certificates issued by other countries. Currently this is the case for 49 countries and territories. The list of these countries can be found in the section Non-EU countries (and territories) that have joined the EU Digital COVID Certificate system on this page. The COVID Certificates issued in these countries are accepted in the EU under the same conditions as the EU Digital COVID Certificate.

Lastly, an EU Member State may, upon request, issue an EU Digital COVID Certificate to a non-EU national wishing to travel to the EU, provided that all reliable proof of vaccination, has been presented, but it is not obliged to do so.

For more details about what rules are in place for non-EU nationals entering from outside the EU, you can consult the Re-open EU website.

Vaccination certificates will be issued to a vaccinated person for any COVID-19 vaccine. The certificate should clearly indicate the name of the vaccine administered.

When it comes to waiving free movement restrictions, Member States only have to accept vaccination certificates for vaccines which received EU marketing authorisation. Member States may also decide to waive restrictions for travellers that received another vaccine, for instance those included on the WHO emergency list, but they are not obliged to. If you have been vaccinated with a vaccine not authorised in the EU, we advise you to check which vaccines are accepted by the respective Member State prior to your travel.

Fully vaccinated persons with the EU Digital COVID Certificate should be exempted from travel-related testing or quarantine 14 days after having received the last dose of a COVID-19 vaccine approved for the entire EU. The same is true for recovered persons with the certificate.

Yes, an EU Digital COVID certificate should be issued already after the first vaccination dose. The number of doses administered will be clearly stated on the vaccination certificate. Member States might not accept a partial vaccination for lifting travel restrictions. Please check national travel restrictions prior to your travel with the national authorities.

Yes. For example if you received doses in two separate Member States, the Member State in which you received the first dose should issue an EU Digital COVID Certificate indicating the first dose. The Member State, which administered the second dose, will then issue an EU Digital COVID Certificate indicating the second dose, once you provide to the authorities there the information confirming the first dose previously received. The same rule applies to the booster shots.

Most Member States have already started to administer COVID-19 vaccine booster doses. An EU Digital COVID Certificate must be issued after the administration of each dose. This means that Member States must also issue a vaccination certificate in the EU Digital COVID Certificate format after the administration of an additional dose.

As of 1 February, new rules also have to be implemented as regards the encoding of booster shots in Certificate. Boosters will be recorded as: 3/3 for a booster dose following a primary 2-dose vaccination series; 2/1 for a booster dose following a single-dose vaccination or a one dose of a 2-dose vaccine administered to a recovered person.

Persons with a negative test in the EU Digital COVID Certificate format should be exempted from possible quarantine requirements, except when they come from areas heavily affected by the virus. The Member States agreed on a standard validity period for tests: 72 hours for PCR tests and, where accepted by a Member State, 48 hours for rapid antigen tests.

Only so-called NAAT tests (including RT-PCR tests) and rapid antigen tests featured in the common list established on the basis of Council Recommendation 2021/C 24/01 are eligible for a test certificate issued under the EU Digital COVID Certificate Regulation. Each Member State can decide whether it accepts rapid antigen tests, or only NAAT tests (such as RT-PCR tests).

Certificates of recovery (indicating that a person has recovered from an infection with COVID-19) can only be issued following a positive NAAT (nucleic acid amplification test) such as RT-PCR test. They can be issued 11 days after the date of the initial test.

The EU Digital COVID Certificate contains necessary key information such as name, date of birth, date of issuance, relevant information about vaccine/ test/recovery, and a unique identifier. This data remains on the certificate and is not stored or retained when a certificate is verified in another Member State.

The certificates will only include a limited set of information that is necessary. This cannot be retained by visited countries. For verification purposes, only the validity and authenticity of the certificate are checked by verifying who issued and signed it. All health data remains with the Member State that issued an EU Digital COVID Certificate.

A valid EU digital COVID certificate includes:

a vaccination certificate where at least 14 and no more than 270 days have passed since the last dose of the primary vaccination series or if the person has received a booster dose

OR

a negative PCR test result obtained no more than 72 hours before travelling or a negative rapid antigen test obtained no more than 24 hours before travelling

OR

a certificate of recovery indicating that no more than 180 days have passed since the date of the first positive PCR test result

At this stage, the Commission does not propose a validity period for certificates issued based on booster shots. This means that the 9-month validity period should not apply to certificates issued following booster shots. It can be expected that protection from booster vaccinations may last longer than that resulting from the primary vaccination series.

The Commission will closely monitor newly emerging scientific evidence on this issue. On this basis, the Commission may, at a later stage, propose if necessary to introduce a validity period also for vaccination certificates issued following a booster if necessary.

EU law covers the use of the EU Digital COVID Certificate to facilitate safe free movement inside the EU.

Member States can also use the COVID-19 certificates for domestic purposes, such as access to events or venues, but this is not regulated at the EU level.

In case a Member State adopts a system of COVID-19 certification for domestic purposes, it should ensure that the EU Digital COVID Certificate is also fully accepted. This is to make sure that travellers going to another Member State do not have to obtain an additional national certificate.

Currently, the Regulation on the EU Digital COVID Certificate applies for 12 months from 1 July 2021. In February 2022, the Commission proposed to extend it by a year, until 30 June 2023. Extending the Regulation would ensure that travellers can continue using their COVID Certificate when travelling in the EU even when Member States maintain certain public health measures.

Find up-to-date information on travel and health measures in European countries, including on quarantine and testing requirements for travellers, to help you exercise your right to free movement. The information is updated frequently and available in 24 languages. This should help you plan your travel in Europe, while staying safe and healthy.

Visit Re-open EU

25 January 2022

Council adopts a revised recommendation on measures ensuring coordination of safe travel in the EU, based on the individual situation of persons and no longer on the region of origin.

21 December 2021

The Commission adopts rules establishing a binding acceptance period of 9 months of vaccination certificates for the purposes of intra-EU travel.

1 July - 12 August 2021

Phase-in period: if a Member State is not yet ready to issue the new certificate to its citizens, other formats can still be used and should be accepted in other Member States.

1 July 2021

The EU Digital COVID Certificate enters into application throughout the EU.

mid-June 2021

Revised Council Recommendation on travel within the EU.

1 - 30 June 2021

Warm-up phase:Member States can launch the certificate on a voluntary basis provided they are ready to issue and verify certificates, and have the necessary legal base in place.

1 June 2021

EU Gateway (interconnection of national systems) goes live.

20 May 2021

The European Parliament and the Council agreed on the EU Digital COVID Certificate.

7 May 2021

The Commission started the pilot test of the EU interoperability infrastructure (EU Gateway) that will facilitate the authentication of the EU Certificates.

22 April 2021

Member States' representatives in theeHealth Networkagreed onguidelinesdescribing the main technical specifications for the implementation of the system. This was a crucial step for the establishment of the necessary infrastructure at EU level.

14 April 2021

The Council adopted its mandate to start negotiations with the European Parliament on the proposal.

17 March 2021

The Commission proposed alegislative textestablishing a common framework for an EU certificate.

27 January 2021

Guidelines laying out interoperability requirements of digital vaccination certificates were adopted, building on discussion held between the Commission and Member States in theeHealth Networksince November 2020.

*This designation is without prejudice to positions on status, and is in line with UNSCR 1244/1999 and the ICJ Opinion on the Kosovo declaration of independence.

Continued here:

EU Digital COVID Certificate | European Commission

Thank you for subscribing to The Corona Letter!

When we sent out the first edition of this newsletter on March 20, 2020, we had a clear mandate to bring the latest, verified information on Covid-19 to keep you safe.

Cases in India had begun to rise from under 10 to about 20 a day and we had seen three deaths due to Covid-19 by then. Though the World Health Organisation had declared it a global pandemic a week earlier, there was more panic than information about the virus and how it spreads. We hoped to fill that gap. Our motto: Caution Yes, Panic No.

Over the next couple of months as the crisis unfolded, we realised how crucial the role of reliable information was. We decoded the virus, its variants, vaccines, symptoms, new research and more, and your feedback and suggestions helped us get better at it every day.

While the virus is still floating around, most of us are fully vaccinated (many have taken the booster dose as well) and more aware of the virus and what to expect. As the spread of the virus eases, we have decided to make The Corona Letter a weekly, instead of a daily, offering. The newsletter will now reach your inbox every Sunday.

Our mandate remains the same. The message for you stays the same too be prepared, stay safe. And remember, its not over, yet.

We look forward to your comments and suggestions to make ourselves more relevant to you.

The Corona Letter Team

Written by: Rakesh Rai, Sushmita Choudhury, Jayanta Kalita, Prabhash K DuttaResearch: Rajesh Sharma

Original post:

Coronavirus Briefing Newsletter - Times of India

In a recent study published in the International Journal of Infectious Diseases, researchers assessed the efficacy of coronavirus disease 2019 (COVID-19) vaccines in people living with human immunodeficiency virus (HIV).

Study: Immunogenicity and efficacy of COVID-19 vaccines in people living with HIV: a systematic review and meta-analysis. Image Credit:Corona Borealis Studio/ Shutterstock

The morbidity, mortality, complications, and significant economic disruption caused by COVID-19 have sped up the discovery of highly effective vaccines to previously unheard-of levels. There is, however, a shortage of information on the effectiveness and safety of vaccines in the people living with HIV (PLWH) groups since vaccine trials did not publish data concerning persons living with HIV. These individuals are of particular interest since the original illness or any concomitant treatments may have suppressed or overactivated their immune systems. In addition, since viral shedding and infection have been noted to be more severe and persistent in PLWH, data on this population are urgently needed.

In the present study, researchers compared the immunogenicity and effectiveness of COVID-19 vaccinations in PLWH with healthy individuals.

The team electronically searched the Cochrane Library, PubMed/Medline, and EMBASE for published articles. First, the research papers were screened by title and abstract, followed by screening the article's full text. Then, two researchers examined each title, abstract, and entire text separately.

The team conducted a meta-analysis of prospective studies that fulfilled the following requirements: patients who received a COVID-19 vaccine of any brand and type; individuals living with HIV/acquired immunodeficiency syndrome (AIDS); articles that included and documented data related to a control group comprising individuals who are not HIV-infected; and studies reporting a minimum of one case of either seroconversion or serological titer values after COVID-19 vaccination.

The team performed a post hoc amendment to include articles that reported data related to prospective observational; qualitative analysis, or experimental studies involving human subjects, all of whom were COVID-19-vaccinated with any vaccine brand and type; studies involving individuals living with HIV/AIDS, and studies that published seroconversion rates of PLWH either with or without a control group.

The setting of the study, primary and secondary outcomes, sample size, inclusion and exclusion criteria, dropout and non-response rates, and study design were all included in the data on study characteristics. Age, sex, and medical history, including immunosuppressive medication history, were all included in the participant information. Eight vaccine types and brands, a dosage schedule, the number of participants who received each kind and brand of vaccination, and the median or mean interval between doses were among the information related to the intervention. Assay type, antibody tested, measurement method, sample collection intervals, and the number of measurements were among the outcome-related variables. Seroconversion following the first and second doses of the COVID-19 vaccine was the primary outcome of interest.

The total number of studies included in the meta-analysis of seroconversion rates was 22. Ten of the 22 studies employed messenger ribonucleic acid (mRNA) vaccines, including BNT162b2 and mRNA-1273; six used inactivated vaccines, including CoronaVac and BBIBP-CorV; five used viral vector vaccines, including AZD1222 and Ad26.CoV2.S; and one used recombinant spike protein nanoparticle vaccines co-formulated with a saponin-based adjuvant, Matrix-M. Among the viral vector vaccines, four studies used AZD1222, including three where it served as the only vaccine, while Ad26.COV2.S was only used in one.

Compared to healthy controls, seroconversion was documented in PLWH in seven investigations following the first dose of the vaccination. The seroconversion rate between healthy controls and PLWH was similar. After receiving a second dose of the vaccine, seroconversion rates among the PLWH were lower than those of healthy controls in 20 studies, including 2,068 PLWH and 4,454 healthy controls. After receiving a second dose of the vaccine, individuals' antibody titers did not appear to be significantly altered or decreased.

After the first and second doses, subgroup analyses were carried out for trials including only mRNA and non-mRNA vaccines. The effects of mRNA vaccinations and non-mRNA vaccines on seroconversion were not noticeably different after the initial dosage. After the second dose, there were no discernible differences in the effects of the mRNA and non-mRNA vaccines on seroconversion.

Overall, the study findings showed that in PLWH, COVID-19 vaccinations exhibited positive immunogenicity and effectiveness. Even though the seroconversion post-second vaccination was marginally lower in PLWH compared to healthy individuals, a second dosage is consistently associated with improved seroconversion. Additional measures, such as a follow-up dose of the mRNA COVID-19 vaccine, could enhance these individuals' seroprotection.

Journal reference:

More here:

COVID-19 vaccines show favorable immunogenicity and efficacy in people living with HIV - News-Medical.Net

Washington. A new Omicron variant of the corona virus seems to be spreading rapidly in America. In a new media report, citing the latest released federal data regarding the Covid-19 virus, there are fears that this new variant could cause big problems. The Wall Street Journal reported in its report that according to Centers for Disease Control and Prevention (CDC) estimates released Friday, 11.4% of the total Covid infection cases found in the United States as of mid-October, both sub-variants of Omicron BQ. 1 and BQ. It was only 1.1.

CDC data shows that both subvariants of Omicron are linked to the ba.5 variant, which was responsible for about 68% of the most recent cases detected in the United States. Experts are also tracking another variant, ba.2.72.2, which in the latest CDC report was found to be responsible for around 1.4% of covid infections.

Also read Corona will wreak havoc again in winter! 2 more dangerous variants of Omicron found in ChinaThe Wall Street Journal quoted Dan Baruch, director of the Center for Virology and Vaccine Research at Beth Israel Deaconess Medical Center in Boston, as saying that this rapid increase in the BQ subvariant indicates that is BA.5. Compared to the variants, they have increased their transmission capacity or their immunity to the vaccine.

Also read Omicrons new XBB sub-variant has also caused a stir in India, so far 71 cases found in 4 states

Previously, a non-peer-reviewed study suggested that BQ.1.1. And other new subvariants might be more resistant to certain antibody therapies.

The number of hospitalized COVID-19 patients in the United States has fallen sharply since the increase in the BA.5 variant since late July. However, the report indicates that in parts of Europe, the number of Covid infections and hospitalizations due to the BA.5 subvariant are increasing again.

Be the first to read the latest news in America News84Media America | Todays Breaking News, Live Updates, Read Most Trusted America News Website News84Media America |

Tags: Coronavirus cases, Covid-19 cases, Omicron variant

FIRST POST: October 15, 2022, 4:29 p.m. HST

,

Here is the original post:

COVID-19 New Variant: A new variant of the corona virus in America has again raised concerns, know the reason - News84Media.com

Yes. The first mass vaccination programme started in early December 2020 and the number of vaccination doses administered is updated on a daily basis here. At least 13 different vaccines (across 4 platforms) have been administered. Campaigns have started in 206 economies.

The Pfizer/BioNtech Comirnaty vaccine was listed for WHO Emergency Use Listing (EUL) on 31 December 2020. The SII/Covishield and AstraZeneca/AZD1222 vaccines (developed by AstraZeneca/Oxford and manufactured by the Serum Institute of India and SK Bio respectively) were given EUL on 16 February. The Janssen/Ad26.COV 2.S developed by Johnson & Johnson, was listed for EUL on 12 March 2021. The Moderna COVID-19 vaccine (mRNA 1273) was listed for EUL on 30 April 2021 and the Sinopharm COVID-19 vaccine was listed for EUL on 7 May 2021. The Sinopharm vaccine is produced by Beijing Bio-Institute of Biological Products Co Ltd, subsidiary of China National Biotec Group (CNBG).

For further information, see here.

Once vaccines are demonstrated to be safe and efficacious, they must be approved by national regulators, manufactured to exacting standards, and distributed. WHO is working with partners around the world to help coordinate key steps in this process, including to facilitate equitable access to safe and effective COVID-19 vaccines for the billions of people who will need them. More information about COVID-19 vaccine development is available here.

Original post:

Coronavirus disease (COVID-19) - World Health Organization

Note: ADHS is open Monday through Friday from 8 a.m. to 5 p.m., except state holidays.

Any documents contained on this Web site that are translations from original text written in English are unofficial and not binding on this state or a political subdivision of this state. To learn about how ADHS collects information about website users, please review our Website Privacy Policy. Los documentos que son traducciones al Espaol y que se encuentran en esta pgina Web no tienen validez oficial ni legal en este Estado o en alguna entidad politica del mismo. 2009 - Arizona Department of Health Services

The public notice and agenda for each public meeting is posted in the lobby of this Department and on the Public Meeting Notices page.

Read this article:

Epidemiology & Disease Control - ADHS

Coronaviruses are a family of viruses known for containing strains that cause potentially deadly diseases in mammals and birds.

In humans they're typically spread via airborne droplets of fluid produced by infected individuals.

Of the seven coronaviruses kown to infect humans, four spread with seasonal regularity, causing anything from mild cold-like symptoms to flu-like discomforts.

A few more notable strains, including SARS-CoV-2 (responsible for COVID-19), and those responsible for severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), can cause death in humans. The cause of death is complex, though is typically the result of heightened immune responses causing damage in multiple systems throughout the body.

First described in detail in the 1960s, the coronavirus gets its name from a distinctive corona or 'crown' of sugary-proteins that projects from the envelope surrounding the particle. Encoding the virus's make-up is the longest genome of any RNA-based virus a single strand of nucleic acid roughly 26,000 to 32,000 bases long.

There are four known genuses in the family, named Alphacoronavirus, Betacoronavirus, Gammacoronavirus, and Deltacoronavirus. The first two only infect mammals, including bats, pigs, cats, and humans. Gammacoronavirus mostly infects birds such as poultry, while Deltacoronavirus can infect both birds and mammals.

Coronaviruses can give rise to a variety of symptoms in different animals. In a high percentage of cases, infection causes no symptoms at all. These individuals can still easily spread the virus without knowing they're infected.

While some strains cause diarrhoea in pigs and in turkeys, in humans infections are usually compared to a bad cold, causing mild to moderate upper respiratory problems such as a runny nose and sore throat.

There are a handful of lethal exceptions, which have had a devastating impact on livestock and human health around the globe. Symptoms in these cases tend to start with a sore throat and fever.

In the specific case of the novel coronavirus COVID-19, most of those infected experience a fever within five days of being infected, followed by a cough. This differs to a flu, which tends to start with a cough.

Severe cases can require hospitalisation from respiratory distress within about a week of the first symptoms showing. Where symptoms continue to worsen, death can follow within two weeks to nearly two months, depending on prognosis and medical care.

COVID-19 is the illness that presents on being infected by a deadly coronavirus called SARS-CoV-2.

This SARS-related virus was first identified in the Chinese city of Wuhan in late 2019. Snakes were originally suspected as a potential source for the outbreak, though other experts have deemed this unlikely and proposed bats as a reservoir instead. Pangolins have been implicated as a potential link in the transfer chain.

As of April 2020, the search for the animal origin of COVID-19 is ongoing.

At the time of writing, numbers of infected are still on the rise, with a mortality rate that varies significantly around the world from less than one to more than 10 percent.

The SARS-CoV-2 pandemic has caused significant disruptions to economies and social activities around the globe throughout 2020. Treatments and protective therapies are currently in development, with programs expected to begin vaccinations in the US by the start of 2021.

SARS was first recognised as a distinct strain of coronavirus in 2003. The source of the virus has never been clear, though the first human infections can be traced back to the Chinese province of Guangdong in 2002.

The virus then became a pandemic, causing more than 8,000 infections of an influenza-like disease in 26 countries with close to 800 deaths.

MERS was first identified in Saudi Arabia in 2012 in people displaying symptoms of fever, cough, shortness of breath and occasionally gastrointestinal problems such as diarrhoea. An animal source for the virus has never been officially confirmed, though evidence points to dromedary camels as a potential reservoir of infection.

The World Health Organisation has identified around 2,500 cases of infection in 27 countries since initial outbreaks, resulting in nearly 860 deaths.

All articles are determined by fact checkers to be correct and relevant at the time of publishing. Information published on the coronavirus during the 2020 COVID-19 pandemic may be updated frequently to reflect the dynamic nature of current understanding.

Read more:

What Is a Coronavirus? : ScienceAlert

The U.S. on Wednesday authorized updated COVID-19 boosters for children as young as 5, seeking to expand protection ahead of an expected winter wave.

Tweaked boosters rolled out for Americans 12 and older last month, doses modified to target todays most common and contagious omicron relative. While there wasnt a big rush, federal health officials are urging that people seek the extra protection ahead of holiday gatherings.

Now the Food and Drug Administration has given a green light for elementary school-age kids to get the updated booster doses, too -- one made by Pfizer for 5- to 11-year-olds, and a version from rival Moderna for those as young as 6.

Theres one more step before parents can bring their kids in for the new shot: The Centers for Disease Control and Prevention, which recommends how vaccines are used, must sign off.

Americans may be tired of repeated calls to get boosted against COVID-19 but experts say the updated shots have an advantage: They contain half the recipe that targeted the original coronavirus strain and half protection against the dominant BA.4 and BA.5 omicron versions.

These combination or bivalent boosters are designed to broaden immune defenses so that people are better protected against serious illness whether they encounter an omicron relative in the coming months -- or a different mutant thats more like the original virus.

We want to have the best of both worlds, Pfizers Dr. Bill Gruber, a pediatrician, told The Associated Press. He hopes the updated shots will re-energize interest in protecting children for the winter.

The updated boosters are extremely important for keeping kids healthy and in school, said Dr. Jason Newland, a pediatric infectious disease specialist at Washington University in St. Louis.

Parents should know there is no concern from the safety perspective with the bivalent vaccines, whether Moderna or Pfizer, Newland added.

Only people whove gotten their initial vaccinations -- with any of the original-formula versions -- qualify for an updated booster. That means about three-fourths of Americans 12 and older are eligible. As of last weekend, only at least 13 million had gotten an updated booster, White House COVID-19 coordinator Dr. Ashish Jha estimated Tuesday.

To pediatricians chagrin, getting children their first vaccinations has been tougher. Less than a third of 5- to 11-year-olds have had their two primary doses and thus would qualify for the new booster.

This age group will get kid-size doses of the new omicron-targeting booster and they can receive it at least two months after their last dose, whether that was their primary vaccination series or an earlier booster, the FDA said.

Vaccination remains the most effective measure to prevent the severe consequences of COVID-19, Dr. Peter Marks, FDAs vaccine chief, said in a statement.

While children tend to get less seriously ill than adults, as the various waves of COVID-19 have occurred, more children have gotten sick with the disease and have been hospitalized, Marks said.

For the updated booster made by Pfizer and its partner BioNTech, 5- to 11-year-olds would get a third of the dose that anyone 12 and older already receives. Pfizer said it could ship up to 6 million kid-sized doses within a week of authorization, in addition to ongoing shipments of adult-sized doses.

Until now, Modernas updated booster was cleared only for adults. FDA just expanded that adult bivalent dosage to 12- to 17-year-olds, and authorized half the dose for kids ages 6 to 11.

As for even younger tots, first vaccinations didnt open for the under-5 age group until mid-June -- and it will be several more months before regulators decide if theyll also need a booster using the updated recipe.

Exactly how much protection does an updated COVID-19 booster shot offer? Thats hard to know. Pfizer and Moderna are starting studies in young children.

But the FDA cleared the COVID-19 booster tweaks without requiring human test results -- just like it approves yearly changes to flu vaccines. Thats partly because both companies already had studied experimental shots tweaked to target prior COVID-19 variants, including an earlier omicron version, and found they safely revved up virus-fighting antibodies.

Its clearly a better vaccine, an important upgrade from what we had before, Jha said earlier this week.

Jha urged adults to get their updated shot in October like they get flu vaccinations or at least well before holiday gatherings with high-risk family and friends. People whove recently had COVID-19 still need the booster but can wait about three months, he added.

___

The Associated Press Health and Science Department receives support from the Howard Hughes Medical Institutes Department of Science Education. The AP is solely responsible for all content.

Read the original:

COVID-19 boosters for kids as young as 5 (Pfizer) or 6 (Moderna) approved by FDA: What parents need to know - OregonLive

Whats more, the mutations in these new strains could make them more immune-evasive, Adalja says. However, even if thats the case, it doesnt necessarily mean they will render protections from the vaccines or a prior infection completely powerless.

The shots weve had access to so far have helped reduce the risk of hospitalization and death in many, regardless of the variants circulating, points out Aditya Shah, an infectious disease specialist at the Mayo Clinic. We hope that that remains, because we dont want to overwhelm the health care systems this winter.

See more Health & Wellness offers >

More than 3,300 Americans are still being hospitalized every day for COVID-19, data from the Centers for Disease Control and Prevention (CDC) shows. And with apotentially rough flu seasonon the horizon, health care workers are bracing for numbers to swell. (During the 20192020 flu season, 390,000 Americans were hospitalized with the illness, according to the CDC.) Cases of RSV (or respiratory syncytial virus, which is most dangerous in infants and older adults) also typically spike in the cold-weather months.

We are entering into the winter months, where no matter what the respiratory disease is, theres always a risk of an uptick in respiratory diseases, Anthony Fauci, M.D., chief medical adviser to the president, said during a recent USC Annenberg Center for Health Journalism webinar.

One thing that could help subdue a storm of hospitalizations this winter: theupdated COVID-19 bivalent booster shots, which are now available to vaccinated people age 12 and older. Arecent reportfrom the Commonwealth Fund finds that if 80 percent of eligible Americans roll up their sleeves for the shot which targets omicrons BA.4 and BA.5 and also the original strain of the virus for a broad swath of protection 936,706 hospitalizations due to COVID-19 could be averted and nearly 90,000 lives could be saved.

If the booster uptake is even equivalent to recent flu vaccine uptake (about half of adults got their flu shot in 20202021, the latest data available shows), more than 75,000 deaths and 745,409 hospitalizations due to COVID-19 could be prevented. Still, few adults (about 4 percent) have received the new booster. About 20 percent of Americans say they arent even aware of them,a recent pollfrom the Kaiser Family Foundation finds. Older adults are the exception, with about half (45 percent) of people age 65 and older reporting they have received the updated booster or intend to get it as soon as possible.

Go here to read the rest:

Protect Yourself From New COVID Variants This Winter - AARP